The complex pathophysiology and clinical management of epidermolysis bullosa: a comprehensive review

INTRODUCTION

Epidermolysis bullosa (EB) encompasses a spectrum of inherited blistering disorders that manifest with extreme skin fragility. Even minimal mechanical trauma can induce blister formation and erosion, underscoring the severe impact of EB on patients' quality of life. EB is divided into four major types: epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), dystrophic epidermolysis bullosa (DEB), and Kindler syndrome. Each subtype is linked to mutations in different genes encoding key structural proteins, such as keratins, laminins, and collagen, which are crucial for maintaining the integrity of the dermo-epidermal junction.^1,2

The clinical manifestations of EB are highly variable, ranging from localized and relatively mild skin involvement in EBS to the severe, life-threatening complications seen in JEB and DEB. In the most severe forms, such as recessive dystrophic EB, patients may develop chronic, non-healing wounds, severe scarring, and an increased risk of squamous cell carcinoma, a significant cause of mortality in this population. Furthermore, extracutaneous manifestations, including mucosal involvement, nail dystrophy, and gastrointestinal complications, contribute to the multisystemic nature of the disease, necessitating a multidisciplinary approach to care.^1,2

Despite significant advances in the understanding of EB's molecular and genetic basis, treatment remains largely supportive, aimed at managing symptoms and preventing complications. However, recent developments in gene therapy, protein replacement therapy, and stem cell therapy are offering new hope for more targeted and potentially curative interventions. This article provides an in-depth review of the pathophysiology, clinical presentation, and emerging therapeutic strategies for EB, with the aim of enhancing the understanding and management of this debilitating group of diseases.^1,2

EPIDEMIOLOGY OF EB

EB is an infrequent yet profoundly impactful group of inherited disorders, with an estimated incidence that varies depending on the specific subtype and geographic region. The overall incidence of EB is approximately 19 to 20 per million live births, with a prevalence ranging from 1 in 50,000 to 1 in 500,000 individuals worldwide. The variation in incidence and prevalence is influenced by several factors, including differences in genetic screening practices, population genetics, and the availability of comprehensive registries in different regions.^1,2

The most common form of EB, EBS, accounts for roughly 70% of all cases, with an incidence estimated at 10 to 12 per million live births. EBS typically presents with milder symptoms and a localized distribution of blisters, often leading to underdiagnosis or misdiagnosis, particularly in settings where genetic testing is less accessible. However, despite its relatively benign course, EBS can still significantly affect the quality of life, particularly in more generalized forms.^3,4

JEB and DEB are less common but are associated with more severe clinical manifestations. JEB, which has an incidence of approximately 2 to 4 per million live births, is further categorized into subtypes based on the severity and specific genetic mutations involved. The generalized severe form of JEB, also known as Herlitz JEB, is often lethal in infancy or early childhood, leading to a lower observed prevalence due to high mortality rates.^3,4

DEB, which occurs in both dominant and recessive forms, has an incidence of about 6 to 7 per million live births. The recessive form of DEB (RDEB) is particularly severe, with widespread blistering, mutilating scarring, and a significantly increased risk of developing aggressive squamous cell carcinoma. The morbidity and mortality associated with RDEB, particularly in its severe generalized form, contribute to a lower overall prevalence compared to the milder dominant form (DDEB).^3,4

Kindler syndrome, the rarest form of EB, is a multisystem disorder characterized by skin fragility, photosensitivity, and progressive poikiloderma. Its incidence is not well defined due to the rarity of the condition and the likelihood of underreporting. However, it is recognized as an autosomal recessive disorder, often seen in consanguineous populations where genetic mutations are more likely to be homozygous.^3,4

Epidemiological studies on EB have been challenging due to the rarity of the condition, the heterogeneity of its clinical manifestations, and the variability in genetic mutations involved. Nonetheless, national and international EB registries have provided valuable data, enabling a better understanding of the distribution, natural history, and burden of disease. These registries, such as the National Epidermolysis Bullosa Registry (NEBR) in the United States and DEBRA International's global database, are crucial for improving epidemiological knowledge, facilitating clinical trials, and guiding public health initiatives.⁵

In addition to genetic factors, epidemiological patterns of EB may also be influenced by environmental and socio-economic factors. For example, access to specialized care and early diagnosis can significantly impact the morbidity and mortality associated with EB, particularly in severe forms like JEB and RDEB. Moreover, the high costs of care, including specialized dressings, wound management, and supportive therapies, pose a significant economic burden on affected individuals and healthcare systems.⁵

In summary, while EB is a rare disorder with a global distribution, its epidemiological profile varies significantly depending on the subtype, genetic factors, and regional healthcare practices. Continued efforts in epidemiological research, including the expansion of registries and genetic screening programs, are essential for advancing the understanding of EB, improving patient outcomes, and optimizing the allocation of healthcare resources.⁶

CLINICAL MANIFESTATIONS OF EB

EB encompasses a broad spectrum of inherited blistering disorders, each presenting with unique clinical manifestations that vary in severity, distribution, and associated complications. The hallmark of all forms of EB is skin fragility, leading to the formation of blisters and erosions following minimal trauma. However, the extent of involvement, extracutaneous manifestations, and disease progression differ significantly across the major subtypes: EBS, JEB, DEB, and Kindler syndrome.⁶

EBS

EBS is the most common and generally mildest form of EB, characterized primarily by intraepidermal blistering due to mutations in the genes encoding keratins 5 and 14.

Clinical manifestations of EBS typically emerge at birth or in early infancy, with blistering confined to sites of friction, such as the hands, feet, and other pressure-prone areas. In milder forms, such as EBS localized (formerly known as Weber-Cockayne type), blisters tend to be small, heal without scarring, and are most pronounced during warmer months when sweating exacerbates friction. Patients with the generalized intermediate form (formerly EBS Koebner) may experience more widespread blistering, particularly during the neonatal period, but still without significant scarring or systemic involvement.⁶

In contrast, the more severe generalized severe form of EBS (formerly Dowling-Meara type) presents with herpetiform clusters of blisters, which may involve large areas of the body. This form can be associated with significant morbidity, including nail dystrophy, hyperkeratosis of the palms and soles, and mucosal involvement. Despite its severity, EBS typically spares the mucous membranes, a key distinguishing feature from other forms of EB.^2,3

JEB

JEB is a rare and often severe form of EB, resulting from mutations in genes encoding components of the hemidesmosomes and the lamina lucida, such as laminin-332 and type XVII collagen. JEB is further subdivided into two major clinical subtypes: generalized severe (formerly Herlitz JEB) and generalized intermediate (formerly non-Herlitz JEB).^3,4

Generalized severe JEB is typically evident at birth, presenting with widespread blistering and erosions that affect both the skin and mucous membranes. The blisters often heal with atrophic scarring and milia formation. In addition to cutaneous involvement, patients frequently exhibit severe mucosal involvement, including oral cavity erosions, respiratory tract lesions, and esophageal strictures, which can lead to feeding difficulties, chronic malnutrition, and life-threatening respiratory complications. The generalized severe form is associated with a high mortality rate in infancy or early childhood due to sepsis, respiratory failure, or severe malnutrition.⁵

Generalized intermediate JEB presents with similar, though less severe, cutaneous and mucosal manifestations. Patients may develop granulation tissue around wounds, particularly in the perioral and perinasal regions. Despite the reduced severity, generalized intermediate JEB still presents significant challenges, including chronic wounds, scarring, and an increased risk of complications such as growth retardation and anemia.⁵

DEB

DEB results from mutations in the COL7A1 gene, which encodes type VII collagen, a critical component of the anchoring fibrils that secure the dermis to the epidermis. DEB is characterized by subepidermal blistering, which can result in extensive scarring and fibrosis. The clinical manifestations of DEB vary widely, with both dominant (DDEB) and recessive (RDEB) inheritance patterns.⁵

In dominant DEB, blistering is often localized, with mild to moderate severity. Patients typically experience blistering on the hands, feet, knees, and elbows, areas most prone to trauma. Healing of these blisters usually results in mild scarring and nail dystrophy, and mucosal involvement is generally limited.⁶

Recessive DEB, particularly the generalized severe form (formerly Hallopeau-Siemens type), presents with profound clinical manifestations. Blistering is widespread, involving both skin and mucous membranes, and heals with significant scarring, leading to pseudosyndactyly (mitten deformities) of the hands and feet. Patients with severe RDEB are at high risk for developing aggressive squamous cell carcinoma (SCC) at chronic wound sites, which is a leading cause of death in this population. Other systemic manifestations of severe RDEB include gastrointestinal involvement (esophageal strictures and dysmotility), ocular complications (corneal scarring and conjunctival inflammation), and dental abnormalities (enamel hypoplasia and caries). Chronic anemia, growth retardation, and osteopenia further complicate the clinical course, contributing to the significant morbidity and reduced life expectancy associated with severe RDEB.⁷

Kindler syndrome

Kindler syndrome is a rare autosomal recessive form of EB caused by mutations in the FERMT1 gene, which encodes kindlin-1, a protein involved in integrin signaling and actin cytoskeleton organization. The clinical manifestations of Kindler syndrome are distinct from other forms of EB, with a progressive nature that evolves over time.⁷

In early infancy, Kindler syndrome may present with blistering that mimics other forms of EB. However, as patients age, they develop additional features such as photosensitivity, poikiloderma (a combination of atrophy, pigmentation, and telangiectasia), and progressive skin fragility. Mucosal involvement is common and can affect the oral cavity, esophagus, genitourinary tract, and conjunctiva, leading to strictures, stenosis, and chronic inflammation. Other complications include gingivitis, periodontal disease, and an increased risk of SCC, particularly in sun-exposed areas.⁷

Extracutaneous manifestations

Beyond the skin, EB frequently involves other organs and systems, depending on the subtype. Mucosal involvement is a common feature, particularly in JEB and severe forms of DEB, affecting the oral cavity, esophagus, genitourinary tract, and respiratory system. This can result in a range of complications, including dysphagia, esophageal strictures, chronic hoarseness, and an increased risk of aspiration pneumonia.⁷

Ocular complications are also prominent in severe forms of EB, with recurrent corneal erosions, conjunctival inflammation, and scarring leading to visual impairment. Dental abnormalities, including enamel hypoplasia, caries, and gingival inflammation, are common in JEB and DEB, contributing to significant oral morbidity.⁷

Nutritional challenges are a significant concern in severe forms of EB, particularly in RDEB and generalized severe JEB. Chronic wounds, mucosal involvement, and esophageal strictures can lead to malnutrition, growth retardation, and failure to thrive. Anemia, secondary to chronic inflammation, blood loss from wounds, and nutritional deficiencies, is also a frequent complication, further impacting the quality of life.⁸

In summary, the clinical manifestations of EB are diverse and complex, with significant variability between and within the different subtypes. The skin fragility that defines EB is just the tip of the iceberg, as many patients experience a wide range of extracutaneous manifestations that require comprehensive, multidisciplinary care. The severity and complexity of EB's clinical presentation underscore the need for ongoing research and development of targeted therapies that address the underlying genetic and molecular defects of this debilitating group of disorders.⁸

CURRENT DIAGNOSTIC METHODS FOR EB

The diagnosis of EB is complex and multifaceted, involving a combination of clinical evaluation, histopathological examination, immunofluorescence mapping, electron microscopy, and increasingly, molecular genetic testing. Given the heterogeneity of EB, accurate diagnosis is essential for determining the specific subtype, guiding treatment, and providing genetic counseling. The diagnostic process is further complicated by the overlap in clinical manifestations between EB subtypes and other blistering disorders, necessitating a comprehensive and systematic approach.⁸

Clinical evaluation

The initial step in diagnosing EB involves a thorough clinical examination, focusing on the pattern, distribution, and severity of blistering, as well as the presence of associated features such as scarring, nail dystrophy, and mucosal involvement. The timing of blister onset, response to trauma, and family history are crucial elements that help narrow down the potential subtype of EB. For instance, blistering that begins at birth or in early infancy, particularly in response to minimal trauma, raises suspicion for more severe forms of EB, such as JEB or DEB.⁸

In addition to skin examination, the assessment should include a detailed evaluation of extracutaneous manifestations, which can provide important diagnostic clues. For example, the presence of esophageal strictures, dental abnormalities, or eye involvement may suggest a more severe subtype of DEB or JEB. A comprehensive family history, including consanguinity and a history of similar symptoms in relatives, is also vital for assessing the likelihood of autosomal recessive versus autosomal dominant inheritance patterns.⁹

Histopathological examination

Skin biopsy remains a cornerstone of EB diagnosis, providing critical information about the level of blister formation and the structural integrity of the dermal-epidermal junction. A biopsy specimen is typically obtained from the edge of a fresh blister, induced by gentle rubbing if necessary, to ensure the inclusion of both lesional and perilesional skin. The specimen is then subjected to standard histopathological examination, which can identify key features such as the level of cleavage within the skin layers, whether intraepidermal, junctional, or subepidermal, helping to classify EB into one of its major subtypes.⁹

Intraepidermal blisters suggest a diagnosis of EBS, while subepidermal blisters are characteristic of DEB. Junctional EB is distinguished by blistering within the lamina lucida of the basement membrane zone. Histopathology can also reveal secondary changes such as hyperkeratosis, acanthosis, or dermal fibrosis, which may be more pronounced in chronic lesions.⁹

Immunofluorescence mapping

Immunofluorescence mapping (IFM) is a highly sensitive diagnostic tool that involves the use of specific antibodies directed against key proteins in the dermal-epidermal junction, such as keratins, laminins, type VII collagen, and integrins. This technique allows for the precise localization of these proteins within the skin and can identify the level of cleavage associated with blister formation.¹⁰

In IFM, skin biopsy specimens are processed using cryosectioning, followed by incubation with fluorescently labeled antibodies. The resulting immunostaining patterns are then examined under a fluorescence microscope. For instance, in EBS, the staining for keratins 5 and 14 will be absent or reduced within the basal keratinocytes, corresponding to the intraepidermal cleavage. In contrast, JEB is characterized by a loss of staining for laminin-332 or type XVII collagen in the lamina lucida, and DEB shows absent or reduced staining for type VII collagen in the anchoring fibrils.¹⁰

IFM is particularly valuable in distinguishing between EB subtypes that may present with overlapping clinical features. It also plays a critical role in confirming the diagnosis in cases where molecular testing is not immediately available.¹⁰

Transmission electron microscopy

Transmission electron microscopy (TEM) is a diagnostic modality that provides ultra-structural details of the skin, allowing for direct visualization of the dermal-epidermal junction at a high resolution. TEM can identify the specific site of cleavage, the integrity of hemidesmosomes, and the presence or absence of anchoring fibrils, which are essential for differentiating between the major subtypes of EB.¹¹

In EBS, TEM typically reveals cleavage within the basal keratinocytes, often associated with keratin filament aggregation. In JEB, the cleavage occurs within the lamina lucida, and the hemidesmosomes may appear disrupted or reduced in number. DEB is characterized by sublamina densa cleavage, with an associated reduction or absence of anchoring fibrils in severe forms. TEM also allows for the identification of ultrastructural anomalies in less common forms of EB, such as Kindler syndrome, where there may be abnormalities in the actin cytoskeleton and focal disruption of the basement membrane zone.¹¹

While TEM is invaluable for providing definitive ultra-structural information, its use has become less frequent due to the complexity, cost, and time required for processing samples. However, it remains an important tool in cases where the diagnosis is unclear or when specific ultra-structural details are required for research or confirmation of rare EB subtypes.¹¹

Molecular genetic testing

Molecular genetic testing has revolutionized the diagnosis of EB, enabling precise identification of the underlying genetic mutations responsible for the disease. This testing involves sequencing the candidate genes known to be associated with EB, such as KRT5, KRT14, COL7A1, LAMA3, LAMB3, and FERMT1, among others. The availability of next-generation sequencing (NGS) has further enhanced the diagnostic process, allowing for the simultaneous analysis of multiple genes in a single test.^10,11

Molecular testing not only confirms the diagnosis and subtype of EB but also provides critical information for genetic counseling, prenatal diagnosis, and the potential for targeted therapies. For example, identifying specific mutations in the COL7A1 gene in DEB patients can guide the use of gene-based therapies, such as gene editing or protein replacement therapy. Similarly, in JEB, identifying mutations in the LAMB3 gene can inform the use of gene therapy strategies, which are currently under investigation.¹¹

The clinical utility of molecular genetic testing extends beyond diagnosis; it also has prognostic implications, as certain mutations are associated with more severe disease phenotypes or specific complications, such as an increased risk of squamous cell carcinoma in severe DEB. As such, molecular testing is increasingly considered the gold standard for EB diagnosis, particularly in cases where the clinical and histopathological findings are ambiguous or when early and accurate diagnosis is essential for patient management.¹¹

Genetic counseling and prenatal diagnosis

Given the hereditary nature of EB, genetic counseling is an integral part of the diagnostic process. Genetic counseling provides affected individuals and their families with information about the inheritance patterns, recurrence risks, and the implications of the disease. In families with a known history of EB, genetic counseling can also facilitate prenatal diagnosis or preimplantation genetic diagnosis (PGD), allowing for early detection of the disease in future pregnancies.¹¹

Prenatal diagnosis typically involves chorionic villus sampling (CVS) or amniocentesis, followed by molecular analysis to detect the specific mutations associated with EB. In cases where the causative mutation is known, PGD can be performed in conjunction with in vitro fertilization (IVF) to select embryos that are free of the disease-causing mutations, offering the possibility of preventing the transmission of EB to future generations.¹¹

Emerging diagnostic techniques

Recent advances in diagnostic technology are continually improving the accuracy and efficiency of EB diagnosis. High-throughput sequencing, including whole-exome sequencing (WES) and whole-genome sequencing (WGS), offers comprehensive analysis of the entire exome or genome, enabling the identification of novel mutations and providing insights into the genetic heterogeneity of EB. These techniques are particularly valuable in diagnosing rare or atypical forms of EB where traditional gene panels may not capture all possible mutations.¹¹

Another promising area of development is non-invasive prenatal testing (NIPT), which analyzes cell-free fetal DNA in maternal blood to detect genetic mutations associated with EB. While still in the research phase, NIPT has the potential to provide an earlier and less invasive option for prenatal diagnosis, particularly in high-risk pregnancies.¹¹

In conclusion, the diagnosis of EB requires a multidisciplinary approach that integrates clinical assessment with advanced laboratory techniques. Histopathology, IFM, TEM, and molecular genetic testing are all essential tools that provide complementary information, leading to an accurate and comprehensive diagnosis. As diagnostic technologies continue to evolve, the ability to diagnose EB early and accurately will improve, ultimately enhancing patient outcomes and guiding the development of targeted therapies for this challenging group of disorders.¹²

CURRENT THERAPEUTIC APPROACHES FOR EB

EB presents as a group of genetic disorders characterized by skin fragility, blistering, and a range of associated complications. The management of EB is complex and multidisciplinary, involving symptomatic treatment, wound care, pain management, nutritional support, and emerging molecular therapies. Given the chronic and often debilitating nature of the disease, therapeutic strategies are primarily focused on improving the quality of life, preventing complications, and addressing the underlying genetic defects where possible.¹²

Wound care and skin management

Wound care is a cornerstone of EB management, as patients are prone to chronic blistering, erosions, and ulcerations. The goals of wound care include promoting healing, preventing infection, minimizing pain, and reducing scarring. Given the variability in EB manifestations, wound care must be individualized based on the type, severity, and location of lesions.¹²

Blister management

The prompt and appropriate management of blisters is critical to prevent complications such as infection and scarring. Blisters should be drained with a sterile needle to prevent further expansion while leaving the roof of the blister intact to act as a natural biological dressing. Non-adherent dressings, such as silicone-coated dressings or hydrogels, are preferred to minimize trauma during dressing changes. Moist wound healing environments are encouraged to promote re-epithelialization and reduce pain.¹²

Infection control

Patients with EB are at high risk for skin infections due to the chronicity of their wounds and the breakdown of the skin barrier. Regular monitoring for signs of infection, such as increased erythema, exudate, or foul odor, is essential. Topical antimicrobials, such as silver sulfadiazine, mupirocin, or honey-based products, are often used to prevent or treat local infections. Systemic antibiotics may be required for more severe or systemic infections, guided by culture and sensitivity testing.¹²

Scar and contracture management

Recurrent blistering and chronic wounds often lead to scarring, contractures, and pseudosyndactyly (mitten deformities) in severe forms of EB, particularly in DEB. Early intervention with physical therapy and splinting can help maintain range of motion and prevent contractures. Silicone gel sheets or corticosteroid injections may be used to manage hypertrophic scars, though surgical interventions such as Z-plasty or skin grafting may be necessary for severe contractures.¹²

Pain management

Pain management is a critical component of EB care, as pain is a significant and often underrecognized symptom that can severely impact the quality of life. Pain in EB can result from blister formation, wound care procedures, chronic ulcers, and associated complications such as esophageal strictures or corneal erosions.¹²

Topical analgesia

Topical anesthetics, such as lidocaine, can be applied before dressing changes or to painful wounds to provide local pain relief. Cooling gels and emollients may also help soothe irritated skin and reduce discomfort.¹²

Systemic analgesia

Systemic pain management may involve the use of nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or opioids, depending on the severity of the pain. Opioids should be used with caution due to the risk of dependency and the need for careful titration. Adjunctive therapies, such as gabapentin or amitriptyline, may be used for neuropathic pain, which is common in chronic wounds and scarred areas.¹²

Psychological support

Chronic pain in EB can lead to significant psychological distress, including anxiety, depression, and social isolation. Multidisciplinary care that includes psychological support, cognitive-behavioral therapy (CBT), and relaxation techniques is essential for managing the emotional and psychological aspects of living with chronic pain.¹²

Nutritional support

Nutritional challenges are prevalent in EB, particularly in more severe subtypes such as JEB and severe DEB. Malnutrition can result from chronic wounds, increased metabolic demands, esophageal strictures, dental abnormalities, and feeding difficulties.¹²

Dietary management

Nutritional support should be tailored to the individual's needs, with a focus on maintaining adequate caloric intake, protein supplementation, and addressing specific deficiencies in vitamins and minerals. High-protein diets are recommended to support wound healing, and supplements such as vitamin C, zinc, and iron may be necessary to correct deficiencies and promote skin integrity.^4,5

Feeding interventions

For patients with significant oropharyngeal or esophageal involvement, modified textures, liquid diets, or enteral feeding may be required. Gastrostomy tubes can be considered for those who are unable to maintain adequate nutrition orally. Esophageal dilatation procedures may also be necessary to manage strictures and improve swallowing.^4,5

Managing complications

Chronic anemia is common in severe EB and may require iron supplementation, erythropoiesis-stimulating agents, or blood transfusions. Bone health should be monitored, and supplementation with calcium and vitamin D, along with weight-bearing exercises, may be recommended to prevent osteopenia and osteoporosis.^4,5

Pharmacological interventions

Several pharmacological agents have been explored in the management of EB, with varying degrees of success. The goal of these therapies is to reduce blister formation, promote wound healing, and address specific complications associated with the disease.^4,5

Tetracyclines

Tetracyclines, such as doxycycline and minocycline, have been used for their anti-inflammatory and matrix metalloproteinase (MMP) inhibitory effects. These antibiotics may help reduce blistering and improve wound healing in some patients with EB, particularly those with JEB or DEB.^4,5

Systemic retinoids

Systemic retinoids, such as acitretin, have been used in the management of hyperkeratotic lesions and epidermal nevi associated with EB. However, their use is limited by potential side effects, including mucocutaneous dryness, teratogenicity, and the risk of exacerbating blistering.^6,7

Topical sirolimus

Sirolimus, an mTOR inhibitor, has shown promise as a topical treatment for hyperkeratotic lesions and chronic wounds in EB. Its anti-inflammatory and immunosuppressive properties may help reduce skin inflammation and promote wound healing.^6,7

Anti-inflammatory agents

Anti-inflammatory agents, including corticosteroids and NSAIDs, may be used to manage inflammation and pain in EB. However, long-term use of systemic corticosteroids is generally avoided due to the risk of side effects, including immunosuppression, osteoporosis, and impaired wound healing.^6,7

Surgical interventions

Surgical interventions may be required to manage complications of EB, including contractures, pseudosyndactyly, esophageal strictures, and aggressive squamous cell carcinoma (SCC). Surgical procedures in EB patients require careful planning and specialized expertise to minimize trauma and complications.^6,7

Hand surgery

Pseudosyndactyly, a common complication in severe DEB, can lead to loss of hand function. Surgical release of contractures, combined with skin grafting or the use of dermal substitutes, can restore function and improve quality of life. Postoperative care is crucial to prevent recurrence, and physical therapy is essential to maintain mobility.^6,7

Esophageal dilation

Esophageal strictures, common in JEB and severe DEB, can lead to dysphagia and malnutrition. Endoscopic dilation procedures are often required to relieve strictures and improve swallowing. Repeated dilations may be necessary over time, and close monitoring for complications such as perforation is essential.^6,7

Management of SCC

SCC is a significant cause of morbidity and mortality in patients with severe DEB. Early detection and aggressive treatment are critical. Surgical excision with clear margins is the primary treatment, but given the high recurrence rate, adjunctive therapies such as Mohs micrographic surgery, radiation therapy, or topical chemotherapy (e.g., 5-fluorouracil) may be considered. Regular skin surveillance and biopsy of suspicious lesions are recommended to detect SCC early.^6,7

Emerging therapies

Recent advances in molecular biology and gene therapy have opened new avenues for the treatment of EB, with the potential to address the underlying genetic defects responsible for the disease. While many of these therapies are still in the experimental or early clinical trial stages, they hold promise for more effective and targeted treatments in the future.^12,13

Gene therapy

Gene therapy aims to correct the underlying genetic mutations in EB by introducing functional copies of the defective gene into the patient’s cells. Various approaches are being explored, including ex vivo gene therapy (where patient cells are modified outside the body and then reintroduced), in vivo gene therapy (direct delivery of gene-editing tools to the affected tissues), and gene editing using technologies such as CRISPR/Cas9. Early clinical trials have shown promising results, particularly in DEB, where the restoration of type VII collagen production has led to improved skin integrity and reduced blistering.^12,13

Protein replacement therapy

Protein replacement therapy involves the administration of functional proteins to compensate for the deficient or defective proteins in EB. For example, intravenous or topical administration of recombinant type VII collagen is being investigated as a treatment for DEB. While still in the experimental stages, protein replacement therapy offers a targeted approach to addressing the molecular defects in EB.^12,13

Cell-based therapies

Cell-based therapies, including the use of stem cells and fibroblast transplantation, are being explored as potential treatments for EB. Mesenchymal stem cells (MSCs) have shown promise in preclinical studies for their ability to reduce inflammation, promote wound healing, and potentially deliver therapeutic proteins. Allogeneic fibroblast transplantation has also been investigated as a means of restoring normal protein expression in the skin. These therapies are still in the early stages of development, and further research is needed to determine their safety.^12,13

CONCLUSION

EB represents a group of devastating genetic disorders characterized by extreme skin fragility, leading to chronic blistering, ulceration, and a host of systemic complications. The heterogeneity of EB, spanning multiple subtypes with varying severity and manifestations, presents significant challenges in diagnosis, management, and therapeutic development. Despite the progress made in understanding the molecular and genetic underpinnings of EB, the disease remains a considerable burden for patients and their families, often resulting in lifelong disability, severe pain, and, in severe cases, early mortality. The current therapeutic landscape for EB is largely centered on symptomatic management, with a primary focus on meticulous wound care, infection control, pain management, nutritional support, and the prevention of complications such as contractures and SCC. These interventions, while essential, are palliative and do not address the root cause of the disease. The high morbidity associated with EB underscores the urgent need for more effective treatments that can improve the quality of life for patients and potentially alter the natural course of the disease. Advancements in molecular genetics and biotechnology have opened new avenues for potential curative therapies, including gene therapy, protein replacement therapy, and cell-based therapies. Gene therapy, in particular, holds promise as a revolutionary approach, with the potential to correct the underlying genetic mutations responsible for EB. Early clinical trials have shown encouraging results, particularly in DEB, where gene therapy has demonstrated the ability to restore normal protein expression and improve skin integrity. However, these therapies are still in their infancy, and significant challenges remain in terms of safety, delivery, and long-term efficacy. As research progresses, it is crucial to continue fostering collaboration among scientists, clinicians, and patient advocacy groups to accelerate the development of these innovative therapies. In parallel, ongoing efforts to improve symptomatic management, enhance wound care techniques, and address the psychosocial aspects of living with EB are essential for improving patient outcomes in the short term. The ultimate goal remains the development of a cure or highly effective treatment that can transform EB from a life-limiting condition into a manageable or even reversible disorder. In conclusion, while significant strides have been made in understanding and managing EB, much work remains to be done. The future of EB treatment lies in the continued advancement of molecular therapies that target the disease at its genetic roots, offering hope for a future where patients with EB can live without the constant threat of blistering and pain. Until then, a multidisciplinary approach that combines cutting-edge research with compassionate clinical care will be essential in supporting those affected by this challenging and complex disorder.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. 1. Fine J, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, et al. The classification of inherited epi- dermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol. 2008;58(6):931-50.
2. 2. El Hachem M, Zambruno G, Bourdon-Lanoy E, Ciasulli A, Buisson C, Hadj-Rabia S, et al. Multicentre con- sensus recommendations for skin care in inherited epidermolysis bullosa. Orphanet J Rare Dis. 2014;9(76):1-20.
3. 3. Fernández C, Ceballos E, Gutiérrez JC. Comprehensive clinical care guide for hereditary epidermolysis bullosa. 2008.
4. 4. Ahmad RC, Bruckner A. A survey of epidermolysis bullosa care in the United States and Canada. Pediatr Dermatol. 2014;31(2):169-75.
5. 5. Mancuso GK, Kopelan B, Azizkhan R, Lucky A. Junctional epidermolysis bullosa incidence and survival: 5-year experience of the Dystrophic Epidermolysis Bullosa Research Association of America (debra) Nurse Educator, 2007 to 2011. Pediatr Dermatol. 2014;31(2):159-62.
6. 6. Yuen Y, Lemmink H, Van Dijk Bos KK, Sinke RJ, Jonkman MF. Herlitz junctional epider- molysis bullosa: diagnostic features, mutational profile, incidence and population carrier frequency in the Netherlands. Br J Dermatol. 2011;165(6):1314-22.
7. 7. Van den Akker P, Jonkman M, Rengaw T, Bruckner-Tuderman L, Has C, Bauer JW, et al. The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their col7a1 mutations. Hum Mutat. 2011;32(10):1100-7.
8. 8. Liy-Wong C, Cepeda R, Salas JC. Epidermolysis bullosa care in Mexico. Dermatol Clinics. 2010;28(2):393-4.
9. 9. Fine JD, Bruckner-Tuderman L, Robin F, Bauer EA, Bauer JW, Has C, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Dematol. 2014;70(6):1103-26.
10. 10. Intong LR, Murrell DF. Inherited epidermolysis bullosa: new diagnostic criteria and classification. Clin Dermatol. 2012;30(2):70-7.
11. 11. Cepeda-Valdés R, Pohla-Gubo G, Borbolla-Escoboza JR, Barboza-Quintana O, Ancer-Rodríguez J, Hintner H, et al. Immunofluorescence mapping for diagnosis of congenital epidermolysis bullosa. Actas Dermosiliogr. 2010;101(8):973-82.
12. 12. Eady R, Dopping P. Transmission electron microscopy for the diagnosis of epidermolysisi bullosa. Dermatol Clin. 2010;28(2):211-22.
13. 13. Salas-Alanís JC, Cepeda-Valdés R, Mellerio JE, Christiano AM, Uitto J. Progress in epider- molysis bullosa: summary of a workshop in cIlad-2010. Int J Dermatol. 2012;51(6):682-7.